Who is sponsoring NCT05911984?

NCT05911984 is sponsored by Mabwell (Shanghai) Bioscience Co., Ltd..

What drugs are being tested in NCT05911984?

Interventions in NCT05911984: 9MW3811 Injection.

What condition does NCT05911984 study?

NCT05911984 studies Advanced Malignant Solid Tumor.

Is NCT05911984 still recruiting?

NCT05911984 is currently status unknown. Last updated 12 June 2023.

Last reviewed 2023-06-12 · How we verify

NCT05911984

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors

Status unknown Phase 1 Last updated 12 June 2023

What this trial tests

Phase 1 trial testing 9MW3811 Injection in Advanced Malignant Solid Tumor in 27 participants. Status unknown.

Timeline

30 June 2023

Primary endpoint
1 March 2024

1 March 2024

Quick facts

Lead sponsor	Mabwell (Shanghai) Bioscience Co., Ltd.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	27
Start date	30 June 2023
Primary completion	1 March 2024
Estimated completion	1 March 2024
Sites	1 location across China

Drugs / interventions tested

9MW3811 Injection — full drug profile →

Conditions studied

Advanced Malignant Solid Tumor — all drugs for Advanced Malignant Solid Tumor →

Sponsor

Mabwell (Shanghai) Bioscience Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Advanced Malignant Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Incidence of adverse events (AEs) as assessed by CTCAE v5.0
Time frame: up to 24 weeks
An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Incidence of dose-limiting toxicity (DLT) as assessed by CTCAE v5.0
Time frame: Cycle 1 Day 1 to Cycle 1 Day 21
A DLT is defined as any of the adverse drug reactions listed in the protocol that will be assessed during Cycle 1

Sponsor's own description

This is a single ascending dose study of 9MW3811, the primary objective of which is to evaluate the safety, tolerability and preliminary efficacy of 9MW3811 in patients with advanced solid tumors.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects.
Cao Z, Quazi S, Arora S, Osellame LD, et al · · 2025 · cited 57× · PMID 39780187 · DOI 10.1186/s12929-024-01099-2
Interleukin-11: A pivotal player and potential therapeutic target in prostate cancer.
Zhong J, Duan X, Wei Z, Zhu W, et al · · 2026 · PMID 41969323 · DOI 10.1097/cu9.0000000000000323

Verify or expand the search:

Other recruiting trials for Advanced Malignant Solid Tumor

Currently open trials in the same condition.

NCT07293754 — An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07050641 — Phase I/II Study of SCTB39-1 in Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
NCT06718946 — Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT06592417 — To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors · Phase 1 · recruiting
NCT05477849 — A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with S · Phase 1 · recruiting

Other Mabwell (Shanghai) Bioscience Co., Ltd. trials

Trials by the same sponsor.

NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07314723 — 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer · Phase 2 · recruiting
NCT06926998 — 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors · Phase 1, PHASE2 · not yet recruiting
NCT06804590 — A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis · Phase 3 · recruiting
NCT06692166 — A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Ca · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05911984 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mabwell (Shanghai) Bioscience Co., Ltd.
Last refreshed: 12 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05911984.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing